{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:03:55Z","timestamp":1788912235979,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"School of Public Health, Tehran University of Medical Science","award":["9711410006"],"award-info":[{"award-number":["9711410006"]}]},{"name":"School of Public Health, Tehran University of Medical Science","award":["9711410006"],"award-info":[{"award-number":["9711410006"]}]},{"name":"School of Public Health, Tehran University of Medical Science","award":["9711410006"],"award-info":[{"award-number":["9711410006"]}]},{"name":"School of Public Health, Tehran University of Medical Science","award":["9711410006"],"award-info":[{"award-number":["9711410006"]}]},{"name":"School of Public Health, Tehran University of Medical Science","award":["9711410006"],"award-info":[{"award-number":["9711410006"]}]},{"name":"School of Public Health, Tehran University of Medical Science","award":["9711410006"],"award-info":[{"award-number":["9711410006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and purpose<\/jats:title>\n                <jats:p>The seroprevalence of antibodies against measles, mumps, and rubella (MMR) was evaluated 17 years following a mass vaccination campaign in individuals aged 2 to 22 years who had received routine immunization but were not eligible for an extended immunization program.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Samples were acquired from Iran\u2019s National Measles Laboratory (NML), with individuals showing positive IgM results excluded. Out of the samples collected in 2020, a random selection of 290 serum samples was chosen, representing individuals between the ages of 2 and 22 years from diverse regions in the country. These samples were subjected to analysis using an enzyme-linked immunosorbent assay (ELISA) to quantify specific IgG antibodies against MMR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The seroprevalence rates of antibodies for measles, mumps, and rubella were determined to be 76.2%, 89.3%, and 76.9%, respectively. Younger age groups exhibited higher seropositivity rates for measles and mumps, whereas the 7- to 11-year-old group demonstrated the highest seropositivity rate for rubella. A reduction in antibody status was observed from younger to older age groups, particularly those aged 17\u201322.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The study unveiled suboptimal antibody levels for measles and rubella, highlighting the necessity for further investigation and potential adjustments to future vaccination strategies. Moreover, the decline in antibody status post-vaccination can accumulate in seronegative individuals over time, elevating the risk of outbreaks.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-024-09593-6","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T13:02:44Z","timestamp":1720789364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Assessing seropositivity of MMR antibodies in individuals aged 2\u201322: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran\u2019s National Measles Laboratory"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9951-7282","authenticated-orcid":false,"given":"Fateme","family":"Ghafoori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talat","family":"Mokhtari-Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas Rahimi","family":"Foroushani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Farahmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azade","family":"shadab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8541-7846","authenticated-orcid":false,"given":"Vahid","family":"Salimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"issue":"1","key":"9593_CR1","doi-asserted-by":"publisher","first-page":"e55043","DOI":"10.1371\/journal.pone.0055043","volume":"8","author":"B Honarvar","year":"2013","unstructured":"Honarvar B, Moghadami M, Moattari A, Emami A, Odoomi N, Bagheri Lankarani K. Seroprevalence of anti-rubella and anti-measles IgG antibodies in pregnant women in Shiraz, Southern Iran: outcomes of a nationwide measles-rubella mass vaccination campaign. PLoS ONE. 2013;8(1):e55043.","journal-title":"PLoS ONE"},{"issue":"2","key":"9593_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.26719\/emhj.21.059","volume":"28","author":"SM Zahraei","year":"2022","unstructured":"Zahraei SM, Izadi S, Gouya MM, Hashemi-Shahri SM, Mohammadi M. Immunization coverage of children aged 24\u201335 months in the Islamic Republic of Iran: a national cluster coverage survey. East Mediterr Health J. 2022;28(2):121\u20139.","journal-title":"East Mediterr Health J"},{"issue":"12","key":"9593_CR3","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1080\/21645515.2016.1214346","volume":"12","author":"SM Zahraei","year":"2016","unstructured":"Zahraei SM, Izadi S, Mokhtari-Azad T. Factors affecting the seroconversion rate of 12-month-old babies after the first injection of measles vaccine in the southeast of Iran. Hum Vaccines Immunotherapeutics. 2016;12(12):3118\u201324.","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"39","key":"9593_CR4","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1016\/j.vaccine.2015.08.057","volume":"33","author":"G Gon\u00e7alves","year":"2015","unstructured":"Gon\u00e7alves G, Frade J, Nunes C, Mesquita JR, Nascimento MSJ. Persistence of measles antibodies, following changes in the recommended age for the second dose of MMR-vaccine in Portugal. Vaccine. 2015;33(39):5057\u201363.","journal-title":"Vaccine"},{"issue":"33","key":"9593_CR5","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1016\/j.vaccine.2017.06.058","volume":"35","author":"HJ Kang","year":"2017","unstructured":"Kang HJ, Han YW, Kim SJ, Kim Y-J, Kim A-R, Kim JA, et al. An increasing, potentially measles-susceptible population over time after vaccination in Korea. Vaccine. 2017;35(33):4126\u201332.","journal-title":"Vaccine"},{"issue":"2","key":"9593_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.vaccine.2019.10.026","volume":"38","author":"SM Zahraei","year":"2020","unstructured":"Zahraei SM, Mokhtari-Azad T, Izadi S, Mohammadi M, Sabouri A. Seroprevalence of anti-rubella and anti-measles antibodies in women at the verge of marriage in Iran. Vaccine. 2020;38(2):235\u201341.","journal-title":"Vaccine"},{"issue":"1","key":"9593_CR7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12913-022-07753-5","volume":"22","author":"R Rezapour","year":"2022","unstructured":"Rezapour R, Dorosti AA, Farahbakhsh M, Azami-Aghdash S, Iranzad I. The impact of the Covid-19 pandemic on primary health care utilization: an experience from Iran. BMC Health Serv Res. 2022;22(1):404.","journal-title":"BMC Health Serv Res"},{"key":"9593_CR8","unstructured":"MOKHTARI AT, ALAVI MM, Yadegari D, SALEHI M, Shahim F, Zareban I. Epidemiologic survey of documented measles outbreak in Tehran. 2004."},{"key":"9593_CR9","doi-asserted-by":"crossref","unstructured":"Nejati J, Sargolzaie N, Kiani M, Mahjoob M, Hashemi A. Measles epidemiology in sistan and baluchistan province during April 2006-March 2011. 2013.","DOI":"10.5812\/jhs.10353"},{"key":"9593_CR10","unstructured":"Asefzadeh M, Peyrovian B. Epidemiological study of measles in Ghazvin, Islamic republic of Iran, April 1997-April 2003. EMHJ-Eastern Mediterranean Health Journal, 12 (1\u20132), 14\u201322, 2006. 2006."},{"issue":"8","key":"9593_CR11","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1086\/529141","volume":"46","author":"MM Cortese","year":"2008","unstructured":"Cortese MM, Jordan HT, Curns AT, Quinlan PA, Ens KA, Denning PM, et al. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis. 2008;46(8):1172\u201380.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"9593_CR12","doi-asserted-by":"publisher","first-page":"e862","DOI":"10.1542\/peds.2006-3451","volume":"120","author":"JK Schaffzin","year":"2007","unstructured":"Schaffzin JK, Pollock L, Schulte C, Henry K, Dayan G, Blog D, et al. Effectiveness of previous mumps vaccination during a summer camp outbreak. Pediatrics. 2007;120(4):e862\u20138.","journal-title":"Pediatrics"},{"key":"9593_CR13","unstructured":"Zahraei S, Gouya M, MOKHTARI AT, Dadras M, Hodaei P, Sabouri A. Descriptive epidemiology of measles in Iran in 1384\u20137. 2009."},{"issue":"1","key":"9593_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-021-05970-7","volume":"21","author":"H Saffar","year":"2021","unstructured":"Saffar H, Khalifeloo M, Saffar M-J, Abdollahi A, Parsaei M-R, Ghorbani G-R, et al. Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran. BMC Infect Dis. 2021;21(1):1\u201310.","journal-title":"BMC Infect Dis"},{"issue":"48","key":"9593_CR15","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.15585\/mmwr.mm6848a1","volume":"68","author":"MK Patel","year":"2019","unstructured":"Patel MK, Dumolard L, Nedelec Y, Sodha SV, Steulet C, Gacic-Dobo M, et al. Progress toward regional measles elimination\u2014worldwide, 2000\u20132018. Morb Mortal Wkly Rep. 2019;68(48):1105.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"31","key":"9593_CR16","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1016\/j.vaccine.2014.04.044","volume":"32","author":"H He","year":"2014","unstructured":"He H, Chen E, Chen H, Wang Z, Li Q, Yan R, et al. Similar immunogenicity of measles\u2013mumps\u2013rubella (MMR) vaccine administrated at 8 months versus 12 months age in children. Vaccine. 2014;32(31):4001\u20135.","journal-title":"Vaccine"},{"issue":"1","key":"9593_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12865-021-00465-1","volume":"23","author":"H Saffar","year":"2022","unstructured":"Saffar H, Mousavi SJ, Saffar H, Parsaei M-R, Ghorbani G-R, Saffar MJ. Seroconversion rates following 2 doses of measles-mumps-rubella vaccination given at the ages 12 and 18 months: data for possible additional dose at older age. BMC Immunol. 2022;23(1):1\u20137.","journal-title":"BMC Immunol"},{"issue":"7","key":"9593_CR18","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s10096-013-1836-6","volume":"32","author":"P Plans","year":"2013","unstructured":"Plans P. New preventive strategy to eliminate measles, mumps and rubella from Europe based on the serological assessment of herd immunity levels in the population. Eur J Clin Microbiol Infect Dis. 2013;32(7):961\u20136.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"9593_CR19","doi-asserted-by":"publisher","first-page":"e94846","DOI":"10.1371\/journal.pone.0094846","volume":"9","author":"V Salimi","year":"2014","unstructured":"Salimi V, Abbasi S, Zahraei SM, Fatemi-Nasab G, Adjaminezhad-Fard F, Shadab A, et al. Implementation of a national measles elimination program in Iran: phylogenetic analysis of measles virus strains isolated during 2010\u20132012 outbreaks. PLoS ONE. 2014;9(4):e94846.","journal-title":"PLoS ONE"},{"issue":"22","key":"9593_CR20","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1016\/j.vaccine.2021.04.012","volume":"39","author":"J Xu","year":"2021","unstructured":"Xu J, Doyon-Plourde P, Tunis M, Quach C. Effect of early measles vaccination on long-term protection: a systematic review. Vaccine. 2021;39(22):2929\u201337.","journal-title":"Vaccine"},{"issue":"2","key":"9593_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jviromet.2005.08.001","volume":"131","author":"BJ Cohen","year":"2006","unstructured":"Cohen BJ, Parry RP, Doblas D, Samuel D, Warrener L, Andrews N, et al. Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay. J Virol Methods. 2006;131(2):209\u201312.","journal-title":"J Virol Methods"},{"issue":"3","key":"9593_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jcv.2006.12.017","volume":"38","author":"A Tischer","year":"2007","unstructured":"Tischer A, Gassner M, Richard J-L, Suter-Riniker F, Mankertz A, Heininger U. Vaccinated students with negative enzyme immunoassay results show positive measles virus-specific antibody levels by immunofluorescence and plaque neutralisation tests. J Clin Virol. 2007;38(3):204\u20139.","journal-title":"J Clin Virol"},{"issue":"10","key":"9593_CR23","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/infdis\/jis568","volume":"206","author":"M Kontio","year":"2012","unstructured":"Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. Waning antibody levels and avidity: implications for MMR Vaccine-Induced Protection. J Infect Dis. 2012;206(10):1542\u20138.","journal-title":"J Infect Dis"},{"issue":"2","key":"9593_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1017\/S0950268899003222","volume":"124","author":"M Paunio","year":"2000","unstructured":"Paunio M, Hedman K, Davidkin I, Valle M, Heinonen OP, Leinikki P, et al. Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Epidemiol Infect. 2000;124(2):263\u201371.","journal-title":"Epidemiol Infect"},{"issue":"4","key":"9593_CR25","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/infdis\/jis719","volume":"207","author":"HA Gans","year":"2013","unstructured":"Gans HA, Yasukawa LL, Sung P, Sullivan B, DeHovitz R, Audet S, et al. Measles Humoral and cell-mediated immunity in children aged 5\u201310 years after primary measles immunization administered at 6 or 9 months of age. J Infect Dis. 2013;207(4):574\u201382.","journal-title":"J Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09593-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09593-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09593-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T13:02:53Z","timestamp":1720789373000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09593-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9593"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09593-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"4 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for this study was obtained from Medical Ethics of Tehran University of Medical Sciences [I R.TUMS.SPH.REC.1401.085]. Written informed consent was obtained from all subjects and\/or their legal guardian(s).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"696"}}